<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1010358</article-id><article-id pub-id-type="publisher-id">ACM-38266</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201000000_15134224.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胃癌患者CD163表达与HER-2表达情况的相关性分析
  Correlation Analysis of CD163 Expression and HER-2 Expression in Patients with Gastric Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>婷婷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>冰睿</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>自民</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院肿瘤内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>10</volume><issue>10</issue><fpage>2372</fpage><lpage>2379</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨M2型肿瘤相关巨噬细胞特异性受体CD163的表达与HER-2基因及预后的相关性分析。方法：随机选择在2013年1月至2019年12月在青岛大学附属医院接受胃癌手术的60例患者。采用免疫组织化学法检测胃癌组织肿瘤相关巨噬细胞标记物的表达情况，采用χ2检验分析CD163表达与临床病理学参数之间的关系。采用Kaplan-Meier生存分析法分析CD163与预后的关系。结果：CD163+肿瘤相关巨噬细胞与肿瘤生物学行为，即TNM分期(P = 0.017)、淋巴结转移(P = 0.009)呈现明显相关，差别有统计学意义，与HER-2表达水平无显著性差异。CD163+肿瘤相关巨噬细胞与胃腺癌患者术后总生存时间，差别无统计学意义。结论：M2型肿瘤相关巨噬细胞特异性受体CD163的表达与TNM分期、淋巴结转移有关，CD163的表达与HER-2基因之间差异无统计学意义。CD163的表达与胃腺癌患者术后总生存时间差别无统计学意义。
    Objective: To investigate the correlation analysis between the expression of M2 tumor-associated macrophage specific receptor CD163 and HER-2 gene and prognosis. Methods: Sixty patients who underwent gastric cancer surgery in Qingdao University Hospital from January 2013 to December 2019 were randomly selected. Immunohistochemistry was used to detect the expression of tumor-related macrophage markers in gastric cancer tissues, and the χ
   <sup>2</sup> test was used to analyze the relationship between CD163 expression and clinicopathological parameters. Kaplan-Meier survival analysis method was used to analyze the relationship between CD163 and prognosis. Results: CD163+ tumor-associated macrophages are related to TNM staging (P = 0.017) and lymph node metastasis (P = 0.009), but there is no significant difference in the expression of HER-2. There was no significant difference in overall survival time between CD163+ tumor-associated macrophages and gastric adenocarcinoma patients. Conclusion: The expression of M2 tumor-associated macrophage specific receptor CD163 is related to TNM staging and lymph node metastasis, and there is no significant difference between the expression of CD163 and HER-2 gene. There was no significant difference between the expression of CD163 and the overall survival time of patients with gastric adenocarcinoma. 
  
 
</p></abstract><kwd-group><kwd>肿瘤相关巨噬细胞，CD163，胃癌，HER-2，预后, Tumor-Associated Macrophages</kwd><kwd> CD163</kwd><kwd> Gastric Cancer</kwd><kwd> HER-2</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨M2型肿瘤相关巨噬细胞特异性受体CD163的表达与HER-2基因及预后的相关性分析。方法：随机选择在2013年1月至2019年12月在青岛大学附属医院接受胃癌手术的60例患者。采用免疫组织化学法检测胃癌组织肿瘤相关巨噬细胞标记物的表达情况，采用χ<sup>2</sup>检验分析CD163表达与临床病理学参数之间的关系。采用Kaplan-Meier生存分析法分析CD163与预后的关系。结果：CD163+肿瘤相关巨噬细胞与肿瘤生物学行为，即TNM分期(P = 0.017)、淋巴结转移(P = 0.009)呈现明显相关，差别有统计学意义，与HER-2表达水平无显著性差异。CD163+肿瘤相关巨噬细胞与胃腺癌患者术后总生存时间，差别无统计学意义。结论：M2型肿瘤相关巨噬细胞特异性受体CD163的表达与TNM分期、淋巴结转移有关，CD163的表达与HER-2基因之间差异无统计学意义。CD163的表达与胃腺癌患者术后总生存时间差别无统计学意义。</p></sec><sec id="s2"><title>关键词</title><p>肿瘤相关巨噬细胞，CD163，胃癌，HER-2，预后</p></sec><sec id="s3"><title>Correlation Analysis of CD163 Expression and HER-2 Expression in Patients with Gastric Cancer<sup> </sup></title><p>Tingting Song, Bingrui Wang, Zimin Liu<sup>*</sup></p><p>Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/25-1571624x4_hanspub.png" /></p><p>Received: Oct. 5<sup>th</sup>, 2020; accepted: Oct. 20<sup>th</sup>, 2020; published: Oct. 27<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/25-1571624x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the correlation analysis between the expression of M2 tumor-associated macrophage specific receptor CD163 and HER-2 gene and prognosis. Methods: Sixty patients who underwent gastric cancer surgery in Qingdao University Hospital from January 2013 to December 2019 were randomly selected. Immunohistochemistry was used to detect the expression of tumor-related macrophage markers in gastric cancer tissues, and the χ<sup>2</sup> test was used to analyze the relationship between CD163 expression and clinicopathological parameters. Kaplan-Meier survival analysis method was used to analyze the relationship between CD163 and prognosis. Results: CD163+ tumor-associated macrophages are related to TNM staging (P = 0.017) and lymph node metastasis (P = 0.009), but there is no significant difference in the expression of HER-2. There was no significant difference in overall survival time between CD163+ tumor-associated macrophages and gastric adenocarcinoma patients. Conclusion: The expression of M2 tumor-associated macrophage specific receptor CD163 is related to TNM staging and lymph node metastasis, and there is no significant difference between the expression of CD163 and HER-2 gene. There was no significant difference between the expression of CD163 and the overall survival time of patients with gastric adenocarcinoma.</p><p>Keywords:Tumor-Associated Macrophages, CD163, Gastric Cancer, HER-2, Prognosis</p><disp-formula id="hanspub.38266-formula35"><graphic xlink:href="//html.hanspub.org/file/25-1571624x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/25-1571624x8_hanspub.png" /> <img src="//html.hanspub.org/file/25-1571624x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>胃癌目前是全球第六大常见癌症类型和第五大癌症死亡原因，该疾病具有高发病率和高死亡率的特点 [<xref ref-type="bibr" rid="hanspub.38266-ref1">1</xref>]。分子生物学已成为胃癌研究的中心领域，肿瘤微环境对肿瘤的发生发展起着关键作用，其中肿瘤相关巨噬细胞(Tumor-associated macrophages TAMs)正逐渐引起人们的关注。</p><p>巨噬细胞是天然免疫反应的参与者，也是实体瘤中白细胞浸润的主要成分。巨噬细胞最初被发现参与抗肿瘤免疫，然而，越来越多的临床前和临床证据表明，TAMs还可以增强肿瘤的发展和转移能力 [<xref ref-type="bibr" rid="hanspub.38266-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.38266-ref3">3</xref>]。在胃癌的发展过程中，大量外周血单核细胞被吸引到肿瘤间质中并被激活成TAMs，TAMs可分为M1型TAMs和M2型TAMs，进展期胃癌中浸润的TAMs常表现为抑制免疫的M2亚型，并在肿瘤的侵袭、转移和血管生成中起着关键性的促进作用 [<xref ref-type="bibr" rid="hanspub.38266-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.38266-ref5">5</xref>]。CD163被认为是M2型巨噬细胞的高度特异性受体 [<xref ref-type="bibr" rid="hanspub.38266-ref6">6</xref>]。</p><p>炎症是癌症的特征之一 [<xref ref-type="bibr" rid="hanspub.38266-ref7">7</xref>]，在胃癌中幽门螺杆菌或其他病原体的感染导致的慢性炎症会削弱M1巨噬细胞的反应，使其处于类M2状态，并增加ROS诱导的巨噬细胞凋亡率，从而增加疾病进展风险 [<xref ref-type="bibr" rid="hanspub.38266-ref8">8</xref>]。包括胃癌在内的几种恶性肿瘤中，M2型巨噬细胞密度高者生存较差。M2型巨噬细胞在印戒细胞癌和粘液腺癌中水平较低，而在低分化腺癌中水平较高 [<xref ref-type="bibr" rid="hanspub.38266-ref9">9</xref>]。Meta分析显示浸润的M2巨噬细胞数可能是胃癌患者的负面预后因素 [<xref ref-type="bibr" rid="hanspub.38266-ref10">10</xref>]。</p><p>人类表皮生长因子受体-2 (HER-2)的发现为胃癌患者带来了新的治疗手段。HER-2阳性患者的靶向治疗药物为曲妥珠单抗，TOGA III期随机试验比较了胃或胃食管交界处腺癌患者单独应用化疗或化疗联合曲妥珠单抗治疗的总生存期，研究结果表明曲妥珠单抗联合化疗与单独化疗相比，OS显著增加(13.8 vs. 11.1个月；P = 0.0046) [<xref ref-type="bibr" rid="hanspub.38266-ref11">11</xref>]。Lindsten T.，Hedbrant A.，Ramberg A.等人的研究表明在乳腺癌患者中，肿瘤相关巨噬细胞的水平与HER-2的表达无相关性 [<xref ref-type="bibr" rid="hanspub.38266-ref12">12</xref>]。然而，在胃癌这一癌种中，HER-2与TAMs的相关性分析的研究尚未有明确结果，本研究旨在分析HER-2表达与M2型肿瘤相关巨噬细胞特异性受体CD163的表达是否存在相关性，以及CD163对胃癌术后患者预后的影响。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>收集2013年1月至2019年12月在青岛大学附属医院接受胃癌手术的患者临床资料，随机选取术后病理为腺癌的患者60例。纳入标准为：术前、术后均未行辅助治疗(放化疗)，FISH检测结果为HER-2基因扩增的患者30例，HER-2基因不扩增的患者30例。</p></sec><sec id="s6_2"><title>2.2. 随访</title><p>对所有纳入研究的患者进行随访，患者总生存时间定义为自手术日期开始至随访日期截止，即截止至2020年04月25日。随访期间患者死亡的总生存时间为手术日期开始至死亡日期截止。</p></sec><sec id="s6_3"><title>2.3. 实验方法</title><sec id="s6_3_1"><title>2.3.1. 实验步骤</title><p>1) 切片脱蜡水化：将石蜡包埋组织块进行连续切片，厚度约4 um。切片经二甲苯脱蜡5 min * 3次，放入无水乙醇中水化5 min * 2次。于95%乙醇水化5 min、70%乙醇水化5 min和50%梯度的乙醇水化5 min，自来水冲洗3 min，蒸馏水冲洗2 min * 2次，随后PBS缓冲液冲洗2 min * 3次。</p><p>2) 抗原修复：将组织玻片置入抗原修复液(PH = 6)，加热修复20 min。蒸馏水冲洗2 min * 2次，PBS缓冲液冲洗5 min * 3次，3%过氧化氢浸泡10 min，蒸馏水冲洗2 min * 2次，PBS缓冲液冲洗5 min * 3次。</p><p>3) 滴加一抗：加入CD163单克隆抗体，37℃放置1小时，PBS缓冲液冲洗5 min * 4次。</p><p>4) 玻片加入二抗，37℃下30 min，继续PBS缓冲液冲洗5 min * 4次。玻片加入3,3-二氨基联苯胺(DAB)常温显色(红色)，显色时间约1 min，自来水冲洗2 min。</p><p>5) 复染与封片：用苏木素染色，自来水冲洗5 min。用于50%的乙醇水化2 min、70%的乙醇水化2 min和95%的乙醇水化2 min，无水乙醇水化2 min * 2次。二甲苯2 min * 2次透明化处理，中性树胶封片。</p></sec><sec id="s6_3_2"><title>2.3.2. 主要试剂</title><p>(1) 一抗CD163单克隆抗体(北京博奥森生物技术有限公司)</p><p>(2) 二抗PV-6002 (中杉金桥生物有限公司)</p><p>(3) DAB显色试剂盒(中杉金桥生物有限公司)</p><p>(4) PBS缓冲液(中杉金桥生物有限公司)</p><p>(5) 枸橼酸盐(中杉金桥生物有限公司)</p><p>(6) 二甲苯(双双化工有限公司)</p><p>(7) 无水乙醇(双双化工有限公司)</p><p>(8) 苏木素(中杉金桥生物有限公司)</p><p>(9) 中性树胶(中杉金桥生物有限公司)</p><p>(10) 过氧化氢(中杉金桥生物有限公司)</p></sec><sec id="s6_3_3"><title>2.3.3. 主要仪器</title><p>(1) 显微镜：奥林巴斯CX31</p><p>(2) 温箱：精宏GMP-9050</p><p>(3) 摄像头：TOUPCAM TP10000A</p><p>(4) 脱水机：Leica ASP300S</p><p>(5) 包埋机：Leica EG1150H</p><p>(6) 切片机：Leica RM2235</p></sec></sec><sec id="s6_4"><title>2.4. 免疫组化染色评分</title><p>免疫组化评分由两名高年资病理医师显微镜下完成。每张切片于肿瘤细胞丰富区域随机取10个高倍镜视野，每视野计数100个细胞，分别按着色强度与着色百分比赋分并求其均值，即着色强度标准：无着色为0分，弱为1分，2分为中度，3分为强。阳性细胞所占百分比标准：阳性细胞数 &lt; 5%为0分，5%~25%为1分，26%~50%为2分，51%~75%为3分，&gt;75%为4分。两者得分进行乘积：0和1分为“−”(阴性)；≥2分为“+”(阳性)。</p></sec><sec id="s6_5"><title>2.5. 统计分析</title><p>所有统计分析均采用SPSS25.0软件进行，CD163与HER-2基因表达及其他临床病理特征比较采用χ<sup>2</sup>检验。术后生存率曲线利用Kaplan-Meier法和对数秩检验估计。对预后影响因素进行COX比例风险模型分析采用多因素分析。P &lt; 0.05被认为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. CD163表达与HER-2及临床病理学关系</title><p>根据免疫组化评分规则将CD163的表达分为阴性和阳性，运用统计分析方法分析其与临床病理特征的关系。如表1所示，CD163阳性与肿瘤生物学行为，即TNM分期、淋巴结转移呈现明显相关，差别有统计学意义。CD163的表达与HER-2表达水平无显著性差异。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The relationship between CD163 and clinicopathological characteristic</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >临床病理特征</th><th align="center" valign="middle" >n (%)</th><th align="center" valign="middle" >CD163阴性 (n = 32) n%</th><th align="center" valign="middle" >CD163阳性 (n = 28) n%</th><th align="center" valign="middle" >χ<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >HER-2基因状态</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >&lt;0.001</td><td align="center" valign="middle"  rowspan="3"  >1.000</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >30 (50)</td><td align="center" valign="middle" >16 (50)</td><td align="center" valign="middle" >14 (50)</td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >30 (50)</td><td align="center" valign="middle" >16 (50)</td><td align="center" valign="middle" >14 (50)</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >2.315</td><td align="center" valign="middle"  rowspan="3"  >0.128</td></tr><tr><td align="center" valign="middle" >≤64</td><td align="center" valign="middle" >32 (53.3)</td><td align="center" valign="middle" >20 (62.5)</td><td align="center" valign="middle" >12 (42.9)</td></tr><tr><td align="center" valign="middle" >&gt;64</td><td align="center" valign="middle" >28 (46.7)</td><td align="center" valign="middle" >12 (37.5)</td><td align="center" valign="middle" >16 (57.1)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.866</td><td align="center" valign="middle"  rowspan="3"  >0.325</td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >38 (63.3)</td><td align="center" valign="middle" >22 (68.8)</td><td align="center" valign="middle" >16 (57.1)</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >22 (36.7)</td><td align="center" valign="middle" >10 (31.3)</td><td align="center" valign="middle" >12 (42.9)</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >浸润程度</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle"  rowspan="3"  >2.232</th><th align="center" valign="middle"  rowspan="3"  >0.135</th></tr></thead><tr><td align="center" valign="middle" >T1~T2</td><td align="center" valign="middle" >15 (25.0)</td><td align="center" valign="middle" >11 (34.4)</td><td align="center" valign="middle" >4 (14.3)</td></tr><tr><td align="center" valign="middle" >T3~T4</td><td align="center" valign="middle" >45 (75.0)</td><td align="center" valign="middle" >21 (65.5)</td><td align="center" valign="middle" >24 (85.7)</td></tr><tr><td align="center" valign="middle" >淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >6.782</td><td align="center" valign="middle"  rowspan="3"  >0.009</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >21 (35.0)</td><td align="center" valign="middle" >16 (50.0)</td><td align="center" valign="middle" >5 (17.9)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >39 (65.0)</td><td align="center" valign="middle" >16 (50.0)</td><td align="center" valign="middle" >23 (82.1)</td></tr><tr><td align="center" valign="middle" >远处转移(腹水涂片阳性)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.365</td><td align="center" valign="middle"  rowspan="3"  >0.564</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >54 (90.0)</td><td align="center" valign="middle" >30 (93.8)</td><td align="center" valign="middle" >24 (85.7)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >6 (10.0)</td><td align="center" valign="middle" >2 (6.3)</td><td align="center" valign="middle" >4 (14.3)</td></tr><tr><td align="center" valign="middle" >TNM分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >5.725</td><td align="center" valign="middle"  rowspan="3"  >0.017</td></tr><tr><td align="center" valign="middle" >I期~II期</td><td align="center" valign="middle" >27 (45.0)</td><td align="center" valign="middle" >19 (59.4)</td><td align="center" valign="middle" >8 (28.6)</td></tr><tr><td align="center" valign="middle" >III期~IV期</td><td align="center" valign="middle" >33 (55.0)</td><td align="center" valign="middle" >13 (40.6)</td><td align="center" valign="middle" >20 (71.4)</td></tr><tr><td align="center" valign="middle" >Laurens分型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="4"  >0.059</td><td align="center" valign="middle"  rowspan="4"  >0.971</td></tr><tr><td align="center" valign="middle" >肠型</td><td align="center" valign="middle" >29 (48.3)</td><td align="center" valign="middle" >15 (46.9)</td><td align="center" valign="middle" >14 (50.0)</td></tr><tr><td align="center" valign="middle" >混合型</td><td align="center" valign="middle" >20 (33.3)</td><td align="center" valign="middle" >11 (34.4)</td><td align="center" valign="middle" >9 (32.1)</td></tr><tr><td align="center" valign="middle" >弥漫型</td><td align="center" valign="middle" >11 (18.3)</td><td align="center" valign="middle" >6 (18.8)</td><td align="center" valign="middle" >5 (17.9)</td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.097</td><td align="center" valign="middle"  rowspan="3"  >0.755</td></tr><tr><td align="center" valign="middle" >低分化</td><td align="center" valign="middle" >33 (55.0)</td><td align="center" valign="middle" >17 (53.1)</td><td align="center" valign="middle" >16 (57.1)</td></tr><tr><td align="center" valign="middle" >中分化</td><td align="center" valign="middle" >27 (45.0)</td><td align="center" valign="middle" >15 (46.9)</td><td align="center" valign="middle" >12 (42.9)</td></tr><tr><td align="center" valign="middle" >神经侵犯</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >1.152</td><td align="center" valign="middle"  rowspan="3"  >0.696</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >23 (38.3)</td><td align="center" valign="middle" >13 (40.6)</td><td align="center" valign="middle" >10 (35.7)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >37 (61.7)</td><td align="center" valign="middle" >19 (59.4)</td><td align="center" valign="middle" >18 (64.3)</td></tr><tr><td align="center" valign="middle" >脉管癌栓</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >2.677</td><td align="center" valign="middle"  rowspan="3"  >0.102</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >26 (43.3)</td><td align="center" valign="middle" >17 (53.1)</td><td align="center" valign="middle" >9 (32.1)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >34 (56.7)</td><td align="center" valign="middle" >15 (46.9)</td><td align="center" valign="middle" >19 (67.9)</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. CD163与临床病理特征的相关性分析</p></sec><sec id="s7_2"><title>3.2. 生存分析</title><p>对60例胃癌患者进行随访，其中20例患者死亡。应用Kaplan-Meier法分析各临床特征与总生存的关系(表2)，胃腺癌手术患者总生存时间与淋巴结转移和TNM分期有关，与年龄、性别、HER-2基因表达、浸润程度、远处转移(腹水涂片阳性)、Laurens分型、分化程度、神经侵犯、脉管癌栓以及CD163的表达差异无统计学意义。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>在实体肿瘤微环境中，巨噬细胞是最丰富的免疫细胞。他们的存在被证实与多种癌症的预后较差相关。肿瘤微环境在维持肿瘤干细胞的未分化状态起着重要作用，并促进肿瘤的进展 [<xref ref-type="bibr" rid="hanspub.38266-ref13">13</xref>]。肿瘤相关巨噬细胞(TAMs)重新编程的能抑制癌症的发展和转移，并可能成为一个有潜在前途的癌症治疗的新靶标 [<xref ref-type="bibr" rid="hanspub.38266-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38266-ref15">15</xref>]。TAMs沿淋巴管淋巴结转移 [<xref ref-type="bibr" rid="hanspub.38266-ref16">16</xref>]。CD163是M2型肿瘤相关巨噬细胞的特异性受体，本课题旨在研究CD163表达情况与HER-2基因及其他临床病理特征的相关性以及CD163与胃腺癌患者术后总生存时间是否存在相关性。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Correlation analysis of clinicopathological parameters and overall survival (OS) in patients with gastric cance</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >临床病理特征</th><th align="center" valign="middle"  rowspan="2"  >n (%)</th><th align="center" valign="middle"  rowspan="2"  >存活人数 (n = ) n%</th><th align="center" valign="middle"  rowspan="2"  >死亡人数 (n = ) n%</th><th align="center" valign="middle"  colspan="2"  >Log-rank检验</th></tr></thead><tr><td align="center" valign="middle" >χ<sup>2</sup></td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >HER-2表达</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.329</td><td align="center" valign="middle"  rowspan="3"  >0.566</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >30 (50.0)</td><td align="center" valign="middle" >19 (47.5)</td><td align="center" valign="middle" >11 (55.0)</td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >30 (50.0)</td><td align="center" valign="middle" >21 (52.5)</td><td align="center" valign="middle" >9 (45.0)</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.010</td><td align="center" valign="middle"  rowspan="3"  >0.921</td></tr><tr><td align="center" valign="middle" >≤64</td><td align="center" valign="middle" >32 (53.3)</td><td align="center" valign="middle" >21 (52.5)</td><td align="center" valign="middle" >11 (55.0)</td></tr><tr><td align="center" valign="middle" >&gt;64</td><td align="center" valign="middle" >28 (46.7)</td><td align="center" valign="middle" >19 (47.5)</td><td align="center" valign="middle" >9 (45.0)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.352</td><td align="center" valign="middle"  rowspan="3"  >0.553</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >38 (63.3)</td><td align="center" valign="middle" >27 (67.5)</td><td align="center" valign="middle" >11 (55.0)</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >22 (36.7)</td><td align="center" valign="middle" >13 (32.5)</td><td align="center" valign="middle" >9 (45.0)</td></tr><tr><td align="center" valign="middle" >浸润程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >1.867</td><td align="center" valign="middle"  rowspan="3"  >0.172</td></tr><tr><td align="center" valign="middle" >T1~T2</td><td align="center" valign="middle" >15 (25.0)</td><td align="center" valign="middle" >12 (30.0)</td><td align="center" valign="middle" >3 (15.0)</td></tr><tr><td align="center" valign="middle" >T3~T4</td><td align="center" valign="middle" >45 (75.0)</td><td align="center" valign="middle" >28 (70.0)</td><td align="center" valign="middle" >17 (85.0)</td></tr><tr><td align="center" valign="middle" >淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >4.565</td><td align="center" valign="middle"  rowspan="3"  >0.033</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >21 (35.0)</td><td align="center" valign="middle" >19 (47.5)</td><td align="center" valign="middle" >2 (10.0)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >39 (65.0)</td><td align="center" valign="middle" >21 (52.5)</td><td align="center" valign="middle" >18 (90.0)</td></tr><tr><td align="center" valign="middle" >远处转移(腹水涂片阳性)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.072</td><td align="center" valign="middle"  rowspan="3"  >0.788</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >54 (90.0)</td><td align="center" valign="middle" >36 (90.0)</td><td align="center" valign="middle" >18 (90.0)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >6 (10.0)</td><td align="center" valign="middle" >4 (10.0)</td><td align="center" valign="middle" >2 (10.0)</td></tr><tr><td align="center" valign="middle" >TNM分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >3.977</td><td align="center" valign="middle"  rowspan="3"  >0.046</td></tr><tr><td align="center" valign="middle" >I期~II期</td><td align="center" valign="middle" >27 (45.0)</td><td align="center" valign="middle" >22 (55.0)</td><td align="center" valign="middle" >5 (25.0)</td></tr><tr><td align="center" valign="middle" >III期~IV期</td><td align="center" valign="middle" >33 (55.0)</td><td align="center" valign="middle" >18 (45.0)</td><td align="center" valign="middle" >15 (75.0)</td></tr><tr><td align="center" valign="middle" >Laurens分型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="4"  >0.092</td><td align="center" valign="middle"  rowspan="4"  >0.955</td></tr><tr><td align="center" valign="middle" >肠型</td><td align="center" valign="middle" >29 (48.3)</td><td align="center" valign="middle" >19 (47.5)</td><td align="center" valign="middle" >10 (50.0)</td></tr><tr><td align="center" valign="middle" >混合型</td><td align="center" valign="middle" >20 (33.3)</td><td align="center" valign="middle" >14 (35.0)</td><td align="center" valign="middle" >6 (30.0)</td></tr><tr><td align="center" valign="middle" >弥漫型</td><td align="center" valign="middle" >11 (18.3)</td><td align="center" valign="middle" >7 (17.5)</td><td align="center" valign="middle" >4 (20.0)</td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.980</td><td align="center" valign="middle"  rowspan="3"  >0.322</td></tr><tr><td align="center" valign="middle" >低分化</td><td align="center" valign="middle" >33 (55.0)</td><td align="center" valign="middle" >20 (50.0)</td><td align="center" valign="middle" >13 (65.0)</td></tr><tr><td align="center" valign="middle" >中分化</td><td align="center" valign="middle" >27 (45.0)</td><td align="center" valign="middle" >20 (50.0)</td><td align="center" valign="middle" >7 (35.0)</td></tr><tr><td align="center" valign="middle" >神经侵犯</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >1.052</td><td align="center" valign="middle"  rowspan="3"  >0.305</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >23 (38.3)</td><td align="center" valign="middle" >17 (42.5)</td><td align="center" valign="middle" >6 (30.0)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >37 (61.7)</td><td align="center" valign="middle" >23 (57.5)</td><td align="center" valign="middle" >14 (70.0)</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >脉管癌栓</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle"  rowspan="3"  >2.039</th><th align="center" valign="middle"  rowspan="3"  >0.153</th></tr></thead><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >26 (43.3)</td><td align="center" valign="middle" >20 (50.0)</td><td align="center" valign="middle" >6 (30.0)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >34 (56.7)</td><td align="center" valign="middle" >20 (50.0)</td><td align="center" valign="middle" >14 (70.0)</td></tr><tr><td align="center" valign="middle" >CD163</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.228</td><td align="center" valign="middle"  rowspan="3"  >0.633</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >32 (53.3)</td><td align="center" valign="middle" >23 (57.5)</td><td align="center" valign="middle" >9 (45.0)</td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >28 (46.7)</td><td align="center" valign="middle" >17 (42.5)</td><td align="center" valign="middle" >11 (55.0)</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 临床病理参数与胃癌患者术后总生存(OS)相关性分析</p><p>相关研究表明，CD163巨噬细胞密度与肿瘤大小、分化程度、淋巴结转移、浸润深度及TNM分期有关 [<xref ref-type="bibr" rid="hanspub.38266-ref17">17</xref>]，然而在本研究中，CD163的表达仅与TNM分期及淋巴结转移相关，与HER-2基因状态无关。这与Lindsten，Hedbrant，Ramberg等人在乳腺癌患者中的研究结果一致 [<xref ref-type="bibr" rid="hanspub.38266-ref12">12</xref>]。</p><p>CD163的表达与胃癌术后患者的预后是否相关仍存在争议。最近的一项Meta分析通过对11篇关于肿瘤相关巨噬细胞(TAMs)是否影响胃癌患者预后的论文进行荟萃分析，结果显示肿瘤相关巨噬细胞(TAMS)不是影响胃癌患者术后总生存时间的独立危险因素 [<xref ref-type="bibr" rid="hanspub.38266-ref18">18</xref>]。然而其他相关研究表明，肿瘤相关巨噬细胞的大量浸润与预后不良密切相关，并在人胃癌上皮–间质转化现象中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.38266-ref19">19</xref>]，M2型肿瘤相关巨噬细胞(TAMs)的浸润已被确定为一个独立的预后因素 [<xref ref-type="bibr" rid="hanspub.38266-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.38266-ref21">21</xref>]。然而本研究结果显示CD163的表达与胃癌患者预后无关。</p><p>然而我们的研究尚存不足，第一巨噬细胞具有较高的可塑性，对不同的刺激，如细胞因子，容易改变其表型，应使用多种可靠的表面标志物进行评估 [<xref ref-type="bibr" rid="hanspub.38266-ref22">22</xref>]；第二这是一个小样本的回顾性分析，仅就胃腺癌这一病理类型进行分析；第三没有研究肿瘤相关巨噬细胞是如何影响胃癌进展的分子机制。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，CD163的表达与HER-2基因表达无关，同时CD163的表达与胃腺癌术后患者的总生存时间无关，尚不能成为预测预后的指标。</p></sec><sec id="s10"><title>同意书</title><p>该研究已获得病人的知情同意。</p></sec><sec id="s11"><title>文章引用</title><p>宋婷婷,王冰睿,刘自民. 胃癌患者CD163表达与HER-2表达情况的相关性分析Correlation Analysis of CD163 Expression and HER-2 Expression in Patients with Gastric Cancer[J]. 临床医学进展, 2020, 10(10): 2372-2379. https://doi.org/10.12677/ACM.2020.1010358</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38266-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
&lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.38266-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wyckoff, J.B., Wang, Y., Lin, E.Y., et al. (2007) Direct Visualization of Macrophage-Assisted Tumor Cell Intravasation in Mammary Tumors. Cancer Research, 67, 2649-2656. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-06-1823</mixed-citation></ref><ref id="hanspub.38266-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Condeelis, J. and Pollard, J.W. (2006) Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis. Cell, 124, 263-266. &lt;br&gt;https://doi.org/10.1016/j.cell.2006.01.007</mixed-citation></ref><ref id="hanspub.38266-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Tauchi, Y., Tanaka, H., Kumamoto, K., et al. (2016) Tumor-Associated Macrophages Induce Capillary Morphogenesis of Lymphatic Endothelial Cells Derived from Human Gastric Cancer. Cancer Science, 107, 1101-1109.  
&lt;br&gt;https://doi.org/10.1111/cas.12977</mixed-citation></ref><ref id="hanspub.38266-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, W.-J., et al. (2017) High Infiltration of Polarized CD163+ Tumor-Associated Macrophages Correlates with Aberrant Expressions of CSCs Markers, and Predicts Prognosis in Patients with Recurrent Gastric Cancer. Journal of Cancer, 8, 363-370. &lt;br&gt;https://doi.org/10.7150/jca.16730</mixed-citation></ref><ref id="hanspub.38266-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lau, S.K., Chun, P.G. and Weiss, L.M. (2004) CD163: A Specific Marker of Macrophages in Paraffin-Embedded Tissue Samples. American Journal of Clinical Pathology, 122, 794-801. &lt;br&gt;https://doi.org/10.1309/QHD6YFN81KQXUUH6</mixed-citation></ref><ref id="hanspub.38266-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Colotta, F., Allavena, P., Sica, A., et al. (2009) Cancer-Related Inflammation, the Seventh Hallmark of Cancer: Links to Genetic Instability. Carcinogenesis, 30, 1073-1081. &lt;br&gt;https://doi.org/10.1093/carcin/bgp127</mixed-citation></ref><ref id="hanspub.38266-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hardbower, D.M., Asim, M., Murray-Stewart, T., et al. (2016) Arginase 2 Deletion Leads to Enhanced M1 Macrophage Activation and Upregulated Polyamine Metabolism in Response to Helicobacter pylori Infection. Amino Acids, 48, 2375-2388. &lt;br&gt;https://doi.org/10.1007/s00726-016-2231-2</mixed-citation></ref><ref id="hanspub.38266-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gambardella, V., Castillo, J., Tarazona, N., et al. (2020) The Role of Tumor-Associated Macrophages in Gastric Cancer Development and Their Potential as a Therapeutic Target. Cancer Treatment Reviews, 86, Article ID: 102015.  
&lt;br&gt;https://doi.org/10.1016/j.ctrv.2020.102015</mixed-citation></ref><ref id="hanspub.38266-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X.L., Jiang, J.T. and Wu, C.P. (2016) Prognostic Significance of Tumor-Associated Macrophage Infiltration in Gastric Cancer: A Meta-Analysis. Genetics &amp; Molecular Research GMR, 15. &lt;br&gt;https://doi.org/10.4238/gmr15049040</mixed-citation></ref><ref id="hanspub.38266-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Bang, Y.J., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet (London, England), 376, 687-697.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(10)61121-X</mixed-citation></ref><ref id="hanspub.38266-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lindsten, T., Hedbrant, A., Ramberg, A., et al. (2017) Effect of Macrophages on Breast Cancer Cell Proliferation, and on Expression of Hormone Receptors, uPAR and HER-2. International Journal of Oncology, 51, 104-114.  
&lt;br&gt;https://doi.org/10.3892/ijo.2017.3996</mixed-citation></ref><ref id="hanspub.38266-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ruffell, B., Affara, N.I. and Coussens, L.M. (2012) Differential Macrophage Programming in the Tumor Microenvironment. Trends in Immunology, 33, 119-126. &lt;br&gt;https://doi.org/10.1016/j.it.2011.12.001</mixed-citation></ref><ref id="hanspub.38266-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ries, C.H., Cannarile, M.A., Hoves, S., et al. (2014) Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell, 25, 846-859. &lt;br&gt;https://doi.org/10.1016/j.ccr.2014.05.016</mixed-citation></ref><ref id="hanspub.38266-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Georgoudaki, A.M., Prokopec, K.E., Boura, V.F., et al. (2016) Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. Cell Reports, 15, 2000-2011.  
&lt;br&gt;https://doi.org/10.1016/j.celrep.2016.04.084</mixed-citation></ref><ref id="hanspub.38266-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Go, Y., Tanaka, H., Tokumoto, M., et al. (2016) Tumor-Associated Macrophages Extend along Lymphatic Flow in the Pre-Metastatic Lymph Nodes of Human Gastric Cancer. Annals of Surgical Oncology, 23, S230-S235.  
&lt;br&gt;https://doi.org/10.1245/s10434-015-4458-7</mixed-citation></ref><ref id="hanspub.38266-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, Q., Wu, X., Tang, M., et al. (2020) Observation of Tumor-Associated Macrophages Expression in Gastric Cancer and Its Clinical Pathological Relationship. Medicine, 99, e19839. &lt;br&gt;https://doi.org/10.1097/MD.0000000000019839</mixed-citation></ref><ref id="hanspub.38266-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Liu, J.Y., Yang, X.J., Geng, X.F., et al. (2016) Prognostic Significance of Tumor-Associated Macrophages Density in Gastric Cancer: A Systemic Review and Meta-Analysis. Minerva Medica, 107, 314.</mixed-citation></ref><ref id="hanspub.38266-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Yan, Y., Yang, Y., et al. (2016) High Infiltration of Tumor-Associated Macrophages Influences Poor Prognosis in Human Gastric Cancer Patients, Associates with the Phenomenon of EMT. Medicine, 95, e2636.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000002636</mixed-citation></ref><ref id="hanspub.38266-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H., Wang, X.F., Shen, Z.B., et al. (2015) Infiltration of Diametrically Polarized Macrophages Predicts Overall Survival of Patients with Gastric Cancer after Surgical Resection. Gastric Cancer, 18, 740-750.  
&lt;br&gt;https://doi.org/10.1007/s10120-014-0422-7</mixed-citation></ref><ref id="hanspub.38266-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Huang, X.P., Pan, Y.M., Ma, J., et al. (2018) Prognostic Significance of the Infiltration of CD163 Macrophages Combined with CD66b Neutrophils in Gastric Cancer. Cancer Medicine, 7, 1731-1741. &lt;br&gt;https://doi.org/10.1002/cam4.1420</mixed-citation></ref><ref id="hanspub.38266-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Pantano, F., Berti, P., Guida, F., et al. (2012) The Role of Macrophages Polarization in Predicting Prognosis in Radically Resected Gastric Cancer. Annals of Oncology, 23, ix538-ix539. &lt;br&gt;https://doi.org/10.1016/S0923-7534(20)34227-7</mixed-citation></ref></ref-list></back></article>